Trouble reading this email? View it in your browser
European Federation of Pharmaceutical Industries and Associations EFPIA Newsletter 28 September 2023
      News
 
  28 September 2023 Evidence shows more than 600 essential medicines at risk, and manufacturing in Europe will...

A proposed restriction on the use of fluorinated substances across the EEA could see the widespread shut down of medicines...

Read more →
 
 
 
  22 September 2023 Orphan medicines: How the draft pharmaceutical legislation proposals would impact rare disease...

As currently drafted, the European Commission proposals contained in the revised legislation would discourage the development...

Read more →
 
 
 
      Blogs
 
  26 September 2023 Affordability of medicines is a two-sided coin (Guest blog)

Pharmaceutical expenditure has remained stable at around 15% of healthcare spending in most European countries over...

Read more →
 
 
 
      Events
 
 
29 SEP 2023
  Are medicines affordable for health systems? Bad Hofgastein, Austria

The myths, the facts, and the way forward

Learn more →
 
 
 
03 OCT 2023
  HETHICO Brussels

Healthcare Ethics & Compliance Conference

Learn more →
 
 
 
05 OCT 2023
  EFPIA Day 2023: A discussion on sustainable ways to reward pharmaceutical innovation... Virtual event

Registrations will close on Monday 2nd October at midday.

Learn more →
 
 
 
05 OCT 2023
  JLABS Program | Non-Confidential Data Presentation as Part of Your Partnering Approach... Leiden (Netherlands) and virtually

The program will focus on the development of pharmaceutical and digital therapeutics.

Learn more →
 
 
      Improving the Attractiveness of the Vaccines Industry in the European Union

Vaccination is one of the most successful health prevention tools, protecting against several infectious diseases. It has allowed us to eradicate smallpox, eliminate polio from nearly every region of the world and control diseases like measles, rubella and pertussis, among many others. Vaccination brings significant value not only to public health but to the economy as well, and should be viewed as an investment, rather than a cost. However, findings from a recent report, highlight several challenges faced by the vaccine industry in Europe across the value chain.

To take full advantage of the benefits that vaccination brings, we need the right environment to encourage vaccine innovation. Discover Vaccines Europe's policy recommendations. 

 
 
      What we are reading
Pharma lobby says EU ban on 'forever chemicals' would halt drug production 27 September 2023  (Reuters) Read more →
Orphan medicines: Impact of draft pharma legislation proposals 25 September 2023  (ThePharmaLetter) Read more →
IHI project GUIDE.MRD banks on better blood tests to detect cancer 18 September 2023  (IHI) Read more →
    About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 36 national associations and 39 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

 
Tel: +32 (0)2 626 25 55
Communications@efpia.eu
▶ in
 
EFPIA 2026 All rights reserved  ·  Disclaimer  ·  Unsubscribe